

Malawi Support for Human Papillomavirus Vaccine (HPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Malawi

2. Routine vaccines grant number: 1921-MWI-19b-X

Routine vaccine introduction grant: 19-MWI-08f-Y

Multi age cohort vaccines grant number: 20-MWI-19c-X

Multi age cohort operation costs grant number: 20-MWI-19e-Y

3. Date of Decision Letter: 12 April 2018

4. Date of the Partnership Framework Agreement: 22 October 2014

5. Programme title: New Vaccine Support (NVS), HPV Routine with multi age cohort in the year of introduction

6. Vaccine type: HPV

- Requested product presentation and formulation of vaccine: HPV Quadrivalent, 1
 dose(s) per vial, LIQUID
- 8. Programme duration¹: 2019 2021
- 9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)

	2019	2020	2021	Total ²
Programme Budget (Routine) (US\$)	2,243,000	1,914,000	2,015,500	6,172,500
Multi Age Cohort Support (US\$)		9,954,500		9,954,500
Total (\$US)	2,243,000	11,868,500	2,015,500	16,127,000

10. Vaccine introduction grant (in US\$): US\$ 674,500

11. Operational support for Multi Age Cohort : Not applicable

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)³

Type of supplies to be purchased with Gavi funds in each year (Routine)	2019
Number of HPV vaccines doses	493,700
Annual Amounts (US\$)	2,243,000

- **13.** Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.
- 14. Self-procurement: Not applicable
- 15. Co-financing obligations: Reference code: 1921-MWI-19b-X-C According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year. 4

Type of supplies to be purchased with Country funds in each year	2019	2020	2021
Number of vaccine doses	22,800	19,400	20,500
Total co-financing payments (US\$) (including freight)	103,500	88,500	93,000

 $^{\rm 3}$ This is the amount that Gavi has approved.

⁴ Co-Financing applies only to the routine cohort. (Multi age cohort is fully financed by Gavi)

16. Additional reporting requirements:	
Reports other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May of each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable	
18. Other conditions: Not applicable	

On behalf of Gavi Signed by,

Hind Khatib-Othman Managing Director, Country Programmes 12 April 2018

Litart. He bill